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Aims Circulating troponin is an important measure of risk in patients with heart failure, but it has not been used to
determine if disease severity influences the responses to drug treatments in randomized controlled trials.
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Methods
and results
In the EMPEROR-Reduced trial, patients with class II–IV heart failure and a reduced ejection fraction were randomly
assigned to placebo or empagliflozin 10 mg daily and followed for the occurrence of serious heart failure and renal
events. High-sensitivity cardiac troponin T (hs-cTnT) was measured in 3636 patients (>97%) at baseline, and patients
were divided into four groups based on the degree of troponin elevation. With increasing concentrations of hs-cTnT,
patients were progressively more likely to have diabetes and atrial fibrillation, to have New York Heart Association
class III–IV symptoms and been hospitalized for heart failure within the prior year, and to have elevated levels of
natriuretic peptides and worse renal function (P-trend< 0.0001 for all comparisons), but importantly, the troponin
groups did not differ with respect to ejection fraction. A linear relationship was observed between the logarithm
of hs-cTnT and the combined risk of cardiovascular death or hospitalization for heart failure (P = 0.0015). When
treated with placebo, patients with the highest levels of hs-cTnT had risks of cardiovascular death and hospitalization
for heart failure that were 3–5 fold greater than those with values in the normal range. Patients with higher levels
of hs-cTnT were also more likely to experience worsening of renal function and serious adverse renal events and
showed the least improvement in health status (as measured by the Kansas City Cardiomyopathy Questionnaire).
When compared with placebo, empagliflozin reduced the combined risk of cardiovascular death or hospitalization
for heart failure, regardless of the baseline level of hs-cTnT, whether the effects of treatment were analysed as
hazard ratios or absolute risk reductions.
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Conclusions Elevations in hs-cTnT reflect the clinical severity, stability and prognosis of patients with heart failure and a reduced
ejection fraction, with biomarkers, comorbidities, clinical course and risks that are proportional to the magnitude
of hs-cTnT elevation. Empagliflozin exerted favourable effects on heart failure and renal outcomes, regardless of the
baseline concentration of hs-cTnT.
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Graphical Abstract
EMPEROR-Reduced: cardiovascular death or hospitalization for heart failure. Forest plot of effect of empagliflozin on the combined risk of
cardiovascular death or hospitalization for heart failure in each of the four troponin groups.
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Introduction
Circulating concentrations of cardiac troponin (troponin I or tro-
ponin T) are increased in many patients with chronic heart fail-
ure with or without coronary artery disease, and these elevations
identify patients with greater severity of disease and who are at
increased risk of major clinical events.1–3 Increases in troponin are
particularly notable in those with worse ventricular function and in
those in whom ejection fraction is more likely to decline and less
likely to recover during long-term follow-up.2,4–6 The level of car-
diac troponin carries powerful prognostic information with respect
to the risk of death or hospitalization, which is independent of ejec-
tion fraction or natriuretic peptides.7–9 However, in most prior
reports, comparisons have been carried out between patients with
normal and abnormal troponins in a dichotomous manner,3 and
therefore, comparatively little is known as to whether the mag-
nitude of elevation of cardiac troponin is important among those
whose concentrations are already in the abnormally elevated range.
Because it is a powerful and objective biomarker of disease
severity and risk, cardiac troponin may be particularly useful in
determining if the severity of heart failure influences the effi-
cacy of sodium–glucose co-transporter 2 (SGLT2) inhibitors.
Both dapagliflozin and empagliflozin reduce the risk of cardio-
vascular death and hospitalization for heart failure in patients




































.. recent meta-analysis suggested that the benefits of these SGLT2
inhibitors may be attenuated in patients with the most advanced
heart failure, as identified by the presence of New York Heart
Association (NYHA) functional class III–IV symptoms.12 However,
these observations were difficult to interpret, since functional
class is a subjective (often unstable) assessment, and measures of
symptoms and exercise tolerance in patients with class II and III
symptoms overlap considerably.13,14 In contrast, cardiac troponin
represents a stable objective measure of disease severity and
prognosis, which adds incrementally to the information provided
by ejection fraction and natriuretic peptides,7–9 and it has been
used to assess whether the severity of risk influences the efficacy
of SGLT2 inhibitors in patients with type 2 diabetes (who largely
did not have heart failure).15 Accordingly, we evaluated the clinical
and prognostic significance of cardiac troponin and its influence
on the efficacy of empagliflozin in patients with heart failure and
a reduced ejection fraction (with and without diabetes) who
participated in the EMPEROR-Reduced trial.
Methods
The design of the EMPEROR-Reduced trial has been described
previously.11 Ethics approval was obtained at each study site, and all
patients provided informed consent; the registration identifier at Clin-
icalTrials.gov is NCT03057977.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Participants had NYHA class II–IV heart failure and an ejection
fraction ≤40%, and were receiving all appropriate treatments for
heart failure. We preferentially enrolled patients with an ejection
fraction of ≤30% by requiring those with higher ejection fractions to
have been hospitalized for heart failure within 12 months or to have
more significantly increased levels of N-terminal prohormone B-type
natriuretic peptide (NT-proBNP). High-sensitivity cardiac troponin
T (hs-cTnT, Roche Diagnostics, Risch-Rotkreuz, Switzerland) was
measured at the baseline visit, and assays were performed at a central
laboratory. Patients were randomized double-blind (in a 1:1 ratio)
to receive placebo or empagliflozin 10 mg daily, in addition to their
usual therapy for heart failure. Following randomization, patients were
periodically assessed for major outcomes and health status related to
heart failure and the need for intensification of diuretic therapy.
The primary endpoint was the composite of cardiovascular death
or hospitalization for heart failure, analyzed as time-to-first event. The
first secondary endpoint was the occurrence of all (first and recurrent)
hospitalizations for heart failure. The second secondary endpoint
was the slope of the change in estimated glomerular filtration rate
(eGFR) during double-blind treatment. Serious adverse renal outcomes
included chronic dialysis, renal transplant, a sustained eGFR reduction
of ≥40%, or a sustained eGFR <15 mL/min/1.73 m2 (if baseline eGFR
≥30) or sustained eGFR <10 mL/min/1.73 m2 (if baseline eGFR <30).
Additional analyses included (i) the two components of the primary
endpoint; (ii) time to reported outpatient intensification of diuretics;
and (iii) changes in the Kansas City Cardiomyopathy Questionnaire
(KCCQ) clinical summary score at 52 weeks. The protocol did not
specify the measurement of hs-cTnT at post-randomization follow-up
visits, and banked blood samples have not yet been analysed for
hs-cTnT.
Outcome measures and statistical
analysis
Values for hs-cTnT were used to define four subgroups of patients.
First, those with a normal reference value (≤14 ng/L) were identified,
and those with elevated values were then divided into tertiles of equal
size, which were designated as having mildly increased, moderately
increased and markedly increased hs-cTnT.
For time-to-first event analyses, between-group differences were
assessed using a Cox proportional hazards model, with pre-specified
covariates of age, gender, region, diabetes, ejection fraction, and eGFR
at baseline. For the analysis of total events, between-group differ-
ences were assessed using a joint frailty model, with cardiovascu-
lar death as a competing risk, using the same covariates as the
time-to-first event analyses. The eGFR slope analysis was based on
on-treatment data using a random coefficient model with age and
baseline eGFR as linear covariates and sex, region, ejection frac-
tion, diabetes, and baseline eGFR-by-time, treatment-by-hs-cTnT, and
treatment-by-time-by-hs-cTnT interaction terms. For the comparison
of absolute risk reduction, between-group event rate differences were
assessed using the Poisson regression model for time-to-first event
analyses and using the negative binomial model for the analysis of total
events, using the same covariates as the time-to-first event analyses.
Additionally, the influence of the logarithm of hs-cTnT on the inci-
dence of cardiovascular death or hospitalization for heart failure was
evaluated by a linear regression analysis, weighted by the number of
patients in each group; because of exceptional skewness, the 1% of
patients with extreme values for cTnT (i.e. >loge >5.0) were excluded



















































































.. Since the four troponin groups were ordered, P-trend tests were
used to evaluate the influence of baseline values for hs-cTnT on (i)
baseline characteristics; (ii) the rates and risks of major heart failure
and renal outcomes in the placebo group; and (iii) the effects of
empagliflozin on heart failure and renal outcomes, using the covariate
adjustments described above.
All analyses of troponin were exploratory and were not described
in the original study protocol.
Results
Of the 3636 randomized patients who had a baseline measure-
ment of hs-cTnT, 803 (22%) patients had a hs-cTNT below the
99th percentile for a normal population (≤14 ng/L). Among those
with an increased hs-cTnT, tertiles were defined as >14–21.3 ng/L,
>21.3–33 ng/L and >33 ng/L, with each tertile comprised of
approximately 26% of the patients. The distribution of values of
hs-cTnT was markedly skewed, with 1% of the patients having val-
ues >150 ng/L.
Relation of troponin and baseline
characteristics
At baseline, we observed a stepwise relationship between increases
in circulating hs-cTnT and clinical measures of heart failure severity
and instability (Table 1). With increasing concentrations of hs-cTnT,
patients were more likely to have NYHA functional class III–IV
symptoms and lower KCCQ scores at baseline, and they were
more likely to have experienced worsening of NYHA class within
3 months or to have been hospitalized for heart failure within the
prior year (P-trend< 0.0001 for all comparisons). As hs-cTnT pro-
gressively increased, there was a parallel stepwise increase in circu-
lating levels of NT-proBNP and uric acid and a stepwise decrease in
eGFR; in addition, the prevalence of diabetes and atrial fibrillation
increased as hs-cTnT levels rose (P-trend< 0.0001 for all compar-
isons). Yet, left ventricular ejection fraction did not differ across the
troponin subgroups, and systolic blood pressure did not decrease
as levels of hs-cTnT increased. Interestingly, as levels of hs-cTnT
progressively increased, there was a stepwise increase in the use
of digitalis glycosides and high doses of loop diuretics, whereas the
utilization of neurohormonal antagonists (beta-blockers, mineralo-
corticoid receptor antagonists and neprilysin inhibitors) progres-
sively decreased (P-trend≤ 0.02 to <0.0001 for all comparisons).
Relation of troponin and clinical course
When treated with placebo and followed for a median of
16 months, there was a stepwise relationship between the
baseline concentration of hs-cTnT and the clinical course of
heart failure. The combined risk of cardiovascular death or
hospitalization for heart failure was 10.0, 17.1, 21.4 and 37.2
events per 100 patient-years of follow-up in patients with
≤14 ng/L, >14–21.3 ng/L, >21.3–33 ng/L and >33 ng/L, respec-
tively (P-trend< 0.0001; Table 2). Cumulative incidence plots of
the risk of a primary endpoint in the four troponin subgroups
are shown in Figure 1A. When troponin was considered as a
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Age (years) 62.0± 11.5 67.1±10.1 68.1±10.8 69.4± 10.7 <0.0001
Women, n (%) 302 (37.6) 245 (26.1) 180 (19.0) 142 (15.0) <0.0001
Race, n (%)
White 519 (64.6) 682 (72.7) 682 (71.9) 682 (72.1) 0.008
Black 72 (9.0) 53 (5.7) 54 (5.7) 68 (7.2)
Asian 166 (20.7) 160 (17.1) 179 (18.9) 157 (16.6)
Region, n (%)
North America 82 (10.2) 104 (11.1) 106 (11.2) 122 (12.9) 0.056
Latin America 307 (38.2) 328 (35.0) 289 (30.5) 334 (35.3)
Europe 250 (31.1) 344 (36.7) 378 (39.8) 337 (35.6)
Asia 99 (12.3) 127 (13.5) 138 (14.5) 122 (12.9)
Clinical course of HF
Duration of HF (years), median (IQR) 3.2 (1.2, 7.7) 4.0 (1.2, 8.8) 4.7 (1.8, 9.7) 4.4 (1.7, 9.1) <0.0001
NYHA functional class III–IV, n (%) 146 (18.2) 210 (22.4) 254 (26.7) 292 (30.8) <0.0001
Worsening NYHA class within 3 months, n (%) 32 (4.0) 56 (6.0) 62 (6.5) 77 (8.1) 0.0003
Hospitalization for HF within 12 months, n (%) 196 (24.4) 293 (31.2) 295 (31.1) 340 (35.9) <0.0001
Body mass index (kg/m2) 27.8± 5.4 27.7± 5.4 27.9± 5.3 28.1± 5.5 0.26
LV ejection fraction (%) 27.5± 5.5 27.3± 6.0 27.5± 6.2 27.5± 6.3 0.91
KCCQ clinical summary score 73.4± 20.5 72.0± 21.5 71.0± 21.6 65.7± 22.6 <0.0001
Systolic blood pressure (mmHg) 120.6±15.1 122.2±15.7 121.8±15.7 123.2±16.1 0.002
Heart rate (bpm) 70.6± 11.6 71.4±11.9 71.3±11.8 71.8±11.7 0.06
NT-proBNP (pg/mL), median (IQR) 1252 (783, 2043) 1678 (1024, 2763) 2168 (1342, 3747) 2847 (1602, 5527) <0.0001
eGFR (mL/min/1.73 m2) 74.0± 19.9 64.3± 19.9 58.6±19.9 52.9± 21.3 <0.0001
Serum uric acid (mg/dL) 6.4±1.8 6.9±1.9 7.3± 2.1 7.7± 2.2 <0.0001
Cardiovascular history, n (%)
Hypertension 523 (65.1) 668 (71.2) 707 (74.5) 731 (77.3) < 0.0001
Prior myocardial infarction 325 (40.5) 400 (42.6) 438 (46.2) 422 (44.6) 0.038
Atrial fibrillation or atrial flutter 225 (28.0) 352 (37.5) 398 (41.9) 426 (45.0) <0.0001
Diabetes mellitus 309 (38.5) 448 (47.8) 481 (50.7) 574 (60.7) <0.0001
Treatment of HF, n (%)
High doses of loop diuretics 118 (14.7) 162 (17.3) 225 (23.7) 293 (31.0) 0.021
Beta-blocker 765 (95.3) 895 (95.4) 904 (95.3) 877 (92.7) 0.013
Mineralocorticoid receptor antagonist 600 (74.7) 683 (72.8) 677 (71.3) 638 (67.4) 0.0005
Sacubitril/valsartan 178 (22.2) 183 (19.5) 193 (20.3) 151 (16.0) 0.003
Cardiac glycosides 90 (11.2) 145 (15.5) 166 (17.5) 177 (18.7) <0.0001
Implantable cardioverter-defibrillatora 217 (27.0) 292 (31.3) 335 (35.3) 291 (30.8) 0.043
Cardiac resynchronization therapyb 46 (5.7) 113 (12.0) 132 (13.9) 142 (15.0) <0.0001
Plus-minus values are means ± standard deviation.
cTnT, high-sensitivity cardiac troponin T (ng/L); eGFR, estimated glomerular filtration rate; HF, heart failure; IQR, interquartile range; KCCQ, Kansas City Cardiomyopathy
Questionnaire; LV, left ventricular; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; NYHA, New York Heart Association.
The median values for hs-cTnT for the four groups are 10.3, 17.5, 25.9 and 47.4, respectively.
P-values refer to the trend test for the relationship between troponin and a specific baseline variable. Patients who self-identified with ≥1 race or with no race are classified
as ‘other’; data for ‘other’ or missing for both race and region are not shown.
aImplantable cardioverter-defibrillator with or without cardiac resynchronization therapy.
bCardiac resynchronization therapy with or without a defibrillator.
continuous variable, a linear relationship was observed between
the logarithm of hs-cTnT and the combined risk of cardiovascu-
lar death or hospitalization for heart failure (Figure 1B) during
double-blind therapy (P = 0.0015).
Additionally, we observed a stepwise relationship between the
circulating level of hs-cTnT and the rate of total hospitalizations
for heart failure, the need for outpatient intensification of diuret-











.. with rates/risks of an event in the highest troponin group being
3–5 times greater than in the normal troponin group (Table 2).
The magnitude of improvement in KCCQ at 52 weeks in the
placebo group was progressively attenuated as hs-cTnT increased.
In parallel, as the baseline values of hs-cTnT increased, there
was a stepwise acceleration in the decline in eGFR over time
and a stepwise increase in the risk of a serious adverse renal
outcome.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Interplay of hs-cTnT and empagliflozin in the EMPEROR-Reduced trial 5










. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiovascular death or hospitalization for
heart failure, n with event (rate per 100 pt-yr)
53 (10.0) 99 (17.1) 122 (21.4) 175 (37.2) <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.71 (1.22, 2.41) 2.20 (1.58, 3.08) 3.68 (2.64, 5.12)
Total (first and recurrent) hospitalizations for
heart failure, n of events
47 117 165 212 <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 2.29 (1.49, 3.52) 3.25 (2.10, 5.01) 5.51 (3.53, 8.58)
Time to first hospitalization for heart failure, n
with event (rate per 100 pt-yr)
36 (6.8) 76 (13.1) 97 (17.0) 125 (26.6) <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.91 (1.27, 2.86) 2.55 (1.72, 3.80) 3.80 (2.56, 5.66)
Cardiovascular death, n with event (rate per
100 pt-yr)
23 (4.1) 37 (5.8) 41 (6.3) 93 (16.3) <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.43 (0.84, 2.43) 1.58 (0.93, 2.68) 4.02 (2.44, 6.61)
All-cause mortality, n with event (rate per 100
pt-yr)
29 (5.2) 53 (8.2) 54 (8.3) 120 (21.0) <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.51 (0.95, 2.40) 1.52 (0.95, 2.43) 3.71 (2.39, 5.77)
Intensification of diuretics, n with event (rate
per 100 pt-yr)
57 (11.2) 87 (15.0) 123 (22.6) 139 (30.4) <0.0001
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.25 (0.89, 1.76) 1.81 (1.31, 2.51) 2.43 (1.74, 3.39)
Change in KCCQ at 52 weeks (adjusted mean,
95% CI)
+5.3 (3.4, 7.2) +4.3 (2.6, 6.1) +3.6 (1.8, 5.4) +2.2 (0.3, 4.2) 0.025
Slope of decline in eGFR (mL/min/1.73 m2/year)
(adjusted mean, 95% CI)
−1.4 (−2.4, −0.3) −2.2 (−3.1, −1.2) −2.3 (−3.2, −1.3) −3.5 (−4.5, −2.4) 0.25
Composite of serious adverse renal outcomes,
n with event (rate per 100 pt-y)
8 (1.8) 14 (2.9) 13 (2.6) 23 (5.3) 0.028
Hazard ratio (95% CI), compared with
cTnT≤14
– 1.53 (0.63, 3.73) 1.51 (0.60, 3.78) 2.67 (1.10, 6.48)
All analyses except for total hospitalizations for heart failure, change in KCCQ and slope of decline in eGFR are time-to-first event.
CI, confidence interval; cTnT, high-sensitivity cardiac troponin T (ng/L); eGFR, estimated glomerular filtration rate; KCCQ, Kansas City Cardiomyopathy Questionnaire; pt-yr,
patient-years.
Influence of troponin on effect
of empagliflozin on clinical outcomes
When compared with placebo, empagliflozin reduced the com-
bined risk of cardiovascular death or hospitalization for heart
mfailure, regardless of the baseline level of hs-cTnT (Table 3).
When considered as a hazard ratio, the magnitude of the effect of
empagliflozin was somewhat larger in patients with hs-cTnT in the
normal range (P-trend = 0.12), but when considered as absolute
risk reduction, the magnitude of the benefit of SGLT2 inhibition was
somewhat larger in patients with the highest hs-cTnT (Graphical
Abstract). When considered as a continuous variable, the treatment
by loge hs-cTnT interaction was nominally significant (P = 0.043)
with a greater effect of empagliflozin on the combined risk of car-
diovascular death or hospitalization for heart failure in patients with
lower levels of hs-cTnT when displayed as a hazard ratio, but not
























.. In addition to the effect on the primary endpoint, empagliflozin
reduced the risk of total hospitalizations for heart failure, first
hospitalizations for heart failure and first intensification of diuret-
ics and was accompanied by an improvement in KCCQ score at
52 weeks. In addition, empagliflozin slowed the rate of decline in
eGFR and decreased the risk of a serious adverse renal outcome.
Because of the relatively small size of the troponin subgroups
and the sparseness of certain events, many of these estimates
were imprecise. Nevertheless, there was no consistent influence
of baseline hs-cTnT on the effects of empagliflozin on these
endpoints (Table 3).
Discussion
In the patients with a reduced ejection fraction who participated in
the EMPEROR-Reduced trial, more than 75% had circulating levels
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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B
Figure 1 (A) Cumulative incidence plots for cardiovascular death or hospitalization for heart failure in placebo-treated patients in four
troponin groups. (B) Weighted regression for the relation of loge troponin and incidence of cardiovascular death or hospitalization for heart
failure in the placebo group. Area in blue depicts 95% confidence intervals. Because of exceptional skewness, the 1% of patients with extreme
values for baseline troponin (i.e. > loge > 5.0) were excluded from this analysis.
of hs-cTnT higher than the normal range for a healthy population,
and we observed a stepwise relationship between the circulating
concentration of hs-cTnT and the severity and instability of heart
failure. Increasing levels of hs-cTnT were associated with progres-
sively lower KCCQ scores and more advanced NYHA functional
class and an increasing likelihood of a recent history of worsen-
ing NYHA class or hospitalization for heart failure. Progressive
increases in hs-cTnT from the normal range to markedly increased
levels were paralleled by a stepwise increase in circulating levels
of NT-proBNP (a marker of cardiac wall stress) and uric acid
(a marker of oxidative stress16) and a stepwise decline in renal
function, and these were accompanied by increasing prevalence
of diabetes and atrial fibrillation. Previous studies have reported





















. most earlier reports evaluated fewer than 1000 patients,8 and none
distinguished the clinical features among patients with increas-
ingly abnormal concentrations of hs-cTnT. In contrast, our novel
finding of statistically compelling concentration-dependent associ-
ations with severity and comorbidities (P-trend< 0.0001) in a large
cohort suggests that our clinical characterization of patients with a
troponin elevation represents replicable findings, despite the mul-
tiplicity of comparisons performed in the current study.
Importantly, a single measurement of hs-cTnT at baseline was a
powerful predictor of both worsening heart failure and renal func-
tion in patients with heart failure and a reduced ejection fraction.
We observed a linear relationship between the natural logarithm
of hs-cTnT and the combined risk of cardiovascular death or hos-
pitalization for heart failure, and as the concentration of hs-cTnT
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Effects of empagliflozin on major heart failure and renal outcomes, according to baseline troponin (hazard
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Cardiovascular death or hospitalization for heart failure (time-to-first event)
Hazard ratio (95% CI) 0.58 (0.37, 0.91) 0.62 (0.45, 0.86) 0.76 (0.58, 1.00) 0.79 (0.64, 0.98) 0.12
Absolute risk reduction (95% CI) 4.1 (0.7, 7.5) 6.6 (2.3, 10.9) 4.9 (−0.1, 9.9) 8.3 (1.2, 15.4) 0.38
Total (first and recurrent) hospitalizations for heart failure
Hazard ratio (95% CI) 0.82 (0.49, 1.37) 0.37 (0.23, 0.57) 0.71 (0.50, 1.01) 0.78 (0.56, 1.07) 0.18
Absolute risk reduction (95% CI) 1.6 (−2.5, 5.7) 12.4 (7.1, 17.7) 8.2 (0.2, 16.2) 9.1 (−2.9, 21.2) 0.36
First hospitalization for heart failure (time-to-event)
Hazard ratio (95% CI) 0.63 (0.37, 1.07) 0.45 (0.30, 0.68) 0.68 (0.50, 0.92) 0.79 (0.62, 1.02) 0.07
Absolute risk reduction (95% CI) 2.5 (−0.4, 5.3) 7.3 (3.8, 10.9) 5.3 (0.9, 9.7) 6.0 (0.0, 12.0) 0.42
Cardiovascular death (time-to-event)
Hazard ratio (95% CI) 0.62 (0.33, 1.23) 1.15 (0.73, 1.81) 1.16 (0.76, 1.77) 0.77 (0.57, 1.03) 0.63
Absolute risk reduction (95% CI) 1.5 (−0.7, 3.6) −0.8 (−3.5, 2.0) −1.1 (−3.9, 1.8) 3.9 (−0.4, 8.1) 0.37
Intensification of diuretics (time-to-event)
Hazard ratio (95% CI) 0.87 (0.59, 1.27) 0.67 (0.48, 0.93) 0.58 (0.44, 0.77) 0.62 (0.48, 0.80) 0.20
Absolute risk reduction (95% CI) 1.3 (−2.7, 5.3) 4.9 (0.8, 9.0) 9.1 (4.2, 14.1) 11.4 (5.2, 17.6) 0.003
Change in KCCQ at 52 weeks (adjusted mean,
95% CI)
+1.7 (−0.9, 4.3) +2.2 (−0.2, 4.6) +1.7 (−0.8, 4.1) +1.4 (−1.1, 3.9) 0.76
Slope of decline in eGFR (mL/min/1.73 m2/year)
(adjusted mean, 95% CI)
+1.3 (−0.1, 2.6) +2.5 (1.3, 3.8) +2.1 (0.8, 3.3) +1.4 (0.1, 2.7) 0.87
Composite of serious adverse renal events (time-to-event)
Hazard ratio (95% CI) 0.65 (0.21, 2.00) 0.23 (0.07, 0.80) 0.37 (0.13, 1.03) 0.63 (0.34, 1.19) 0.49
Absolute risk reduction (95% CI) 0.6 (−1.0, 2.3) 2.2 (0.6, 3.9) 1.6 (−0.1, 3.3) 2.0 (−0.8, 4.7) 0.51
Shown are the hazard ratios of the effects of empagliflozin with placebo. Absolute risk reductions are displayed as risk in the placebo group minus the risk in the empagliflozin
group in events per 100 patient-years of follow-up.
CI, confidence interval; cTnT, high-sensitivity cardiac troponin T (ng/L); eGFR, estimated glomerular filtration rate; KCCQ, Kansas City Cardiomyopathy Questionnaire.
progressively increased, there was a stepwise increase in the subse-
quent risk of cardiovascular death, total hospitalizations for heart
failure and outpatient intensification of diuretics, and there was
a stepwise acceleration in the decline in eGFR over time and a
stepwise increase in the risk of a serious adverse renal outcome.
Remarkably, patients in the highest hs-cTnT group had risks that
were 3–5 fold greater than those with values in the normal range.
The prognostic importance of hs-cTnT has been well-documented
in numerous reports of patients with heart failure,7–9,19,22,23 but
most earlier studies simply dichotomized patients into groups
with ‘normal’ and ‘abnormal’ values (without distinguishing among
patients with elevated hs-cTnT), and only one study reported the
ability of troponin to predict worsening renal function (although
not in patients with heart failure).24 A few studies8,9,23,25 have noted
a stepwise relationship between hs-cTnT and mortality in patients
with heart failure, but in these reports, nearly 50% of the patients
had values in the normal range; most patients were not receiv-
ing modern-day neurohormonal antagonists; and none examined
the relationship of hs-cTnT to non-fatal heart failure events. Inter-
estingly, hs-cTnT had powerful prognostic importance even though
patients with elevated hs-cTnT concentrations in the current study
did not have lower left ventricular ejection fractions or lower sys-
tolic blood pressures, in contrast to most previous reports.9,19–21
It seems likely that the prognostic importance of hs-cTnT is




































.. clinical instability of heart failure as well as its ability to reflect
the existence of critical comorbidities (diabetes, atrial fibrillation
and chronic kidney disease) that are known to be accompanied
by an accelerated rate of progression of heart muscle dysfunc-
tion, although these were not reflected by the measurement of
ejection fraction or systolic blood pressure in the current analy-
sis. However, it is noteworthy that, as levels of hs-cTnT progres-
sively increased, there was increased utilization of drugs that have
been associated with an increased mortality (i.e. digitalis glyco-
sides and high doses of loop diuretics26,27) and decreased utiliza-
tion of neurohormonal antagonists that have favourable effects on
survival (i.e. beta-blockers, mineralocorticoid receptor antagonists
and neprilysin inhibitors). Similar associations with background
therapy have been reported by others.8,18–20 The finding that the
effect of neprilysin inhibition to slow the progression of heart fail-
ure is accompanied by an early decrease in troponin28 suggests that
the effect of drugs on troponin may parallel their effects on the risk
of death. Changes in the concentration of troponin have prognostic
significance that adds to the information provided by the baseline
value.20
The ability of hs-cTnT to objectively assess the clinical severity
of heart failure allowed us to determine if patients with advanced
heart failure respond as favourably to SGLT2 inhibition as do
patients with mild-to-moderate disease. Recent evidence suggests
that disease severity may influence the magnitude of the benefits
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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A
B
Figure 2 Relation of baseline troponin and the effect of empagliflozin on cardiovascular death or hospitalization for heart failure, displayed
as a hazard ratio (A) and as absolute risk reduction (B). Area in blue depicts 95% confidence intervals (CI). Because of exceptional skewness,
the 1% of patients with extreme values for baseline troponin (i.e. > loge > 5.0) were excluded from this analysis.
of certain drugs for heart failure; e.g. the response to vericiguat
appears to be attenuated in patients with markedly increased
levels of natriuretic peptides29 and the response to omecamtiv
mecarbil appears to be enhanced in patients with very low ejection
fractions.30 We could not rely on these two biomarkers of disease
severity in the EMPEROR-Reduced trial, since we designed the
study to enrich our patient population for low values for ejection
fraction and high values for natriuretic peptides. Consequently,
we elected to use hs-cTnT as a primary measure of heart failure
severity (in accordance with the findings of others23), and we noted
that empagliflozin reduced the combined risk of cardiovascular
death or hospitalization for heart failure, regardless of the baseline
level of hs-cTnT. When considered as a hazard ratio, the magnitude
of the effect of empagliflozin was somewhat larger in patients
with hs-cTnT concentrations in the normal range, but when
considered as absolute risk reduction, the magnitude of the benefit
of SGLT2 inhibition was somewhat larger in patients with the
highest hs-cTnT. Taken collectively, these observations alleviate
concerns raised by a recent meta-analysis that suggested that
the benefits of SGLT2 inhibitors may be attenuated in patients
with NYHA functional class III–IV symptoms.12 However, unlike
































.. is prone to rapid changes,13,14 and thus, it is not poised to
reliably distinguish responders and non-responders to treatment.
For example, concerns that sacubitril/valsartan may be less effective
in class III–IV patients based on subgroup analysis of one large-scale
trial31 were not confirmed in a later study that demonstrated the
efficacy of neprilysin inhibition in severely limited patients.32
The findings of the present study should be interpreted in
the context of its strengths and limitations. The current analysis
represents one of the largest and most detailed examinations
of the clinical features and prognostic implications of hs-cTnT,
and it is the first trial to evaluate the influence of troponin on
the response to drug treatment in heart failure. However, the
EMPEROR-Reduced trial was designed to focus on higher-risk
patients, thus explaining why only one-fifth of our patients had
values for hs-cTnT in the normal range, a proportion that was
lower than earlier reports.8,9,19,20 Nevertheless, the large number
of patients with abnormally increased hs-cTnT allowed us to
examine stepwise relationships among those with elevated values,
which previous studies were unable to do. Importantly, in the
current analysis, we measured hs-cTnT only at baseline, and thus,
we have not evaluated the effects of empagliflozin on troponin or
the meaningfulness of drug-induced changes in troponin on the
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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clinical status and prognosis of patients. These assessments are
currently planned, since hs-cTnT is one of several key biomarkers
that we will be measuring on blood samples that were prospectively
collected and banked during the trial.
In conclusion, our findings demonstrate that elevations in
hs-cTnT reflect the clinical severity, stability and prognosis of
patients with heart failure and a reduced ejection fraction, with
biomarkers, comorbidities and risks that are proportional to the
magnitude of hs-cTnT elevation. Patients with the highest hs-cTnT
had risks that were generally >3-fold greater than those with values
in the normal range. Empagliflozin exerted favourable effects on
heart failure and renal outcomes, regardless of the baseline con-
centration of hs-cTnT.
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